STAT3 and breast carcinoma: Although further studies involving the assessment of STAT3 inhibition in combination with immunotherapies are needed, the comprehensive crosstalk between STAT3-dependent pathways and immune checkpoints presents an attractive therapeutic target in breast cancer (Figure 2).